Resource
The Summer Myeloma Today Edition has highlights of the 2021 IMWG Summit, 2021 ASCO and EHA Meeting Overview, Venetoclax Trials Showing Efficacy in t(11:14) Myeloma, IMF Honoring Leaders in the Field of Myeloma, and more news!
Resource
The Spring Myeloma Today Edition has recent COVID-19 information, CAR T-cell therapy made simple, 2021 ONS Satellite Symposium, Myeloma Action Month impact and more news!
Resource
Xpovio is a nuclear export inhibitor to treat Myeloma
Resource
The Winter Myeloma Today Edition has Key Updates on COVID-19, FDA Myeloma Therapy Approvals, and Other Scientific Updates
Resource
In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading recommendations using the Grading of…
Resource
Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect and isotype Mproteins. Increasing demands to detect low-level disease and new…
Resource
The policy review presents recommendations from the International Myeloma Working Group for the treatment of relapsed and refractory multiple myeloma. Based on phase 2 and phase 3 trial results, the recommendations are intended for patients who have received one or more previous lines of therapy…
Resource
The IMF marks its 30th Anniversary with a Virtual Comedy Celebration
Resource
Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). The International Myeloma Working Group (IMWG) has developed a risk stratification model for SMM based on three independent factors: serum M-protein >2 g/dL, involved to uninvolved free light-chain…
Resource
Highlights of Virtual 2020 Annual Meetings of ASCO and EHA, A New Class of Drugs, New Agents, and Clinical Trial Updates
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Immunotherapy in Myeloma: Attacking the Plasma Cell in New Ways
The FDA Approves Isatuximab-irfc (Sarclisa®) for Relapsed Refractory…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
2019 ASH Highlights
2020 IMF Brian D. Novis Research Grant
International Activities
…
Resource
Dear Reader
A message from IMF President Susie Novis
Special Event
Puttin' On The Ritz
Scientific & Clinical
Great Debates in Myeloma
Selinexor for Refractory…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Highlights of the 55th Annual Meeting of the American Society of Clinical Oncology
Report from the 2019 Summit of the International…
Resource
Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal…
Resource
As treatment for myeloma improves and patients live longer, it is important to reduce the disability that can result from the painful problem of vertebral compression fractures, which occur when the vertebra collapses or fractures because the bone is too weak to withstand the pressure or stress…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
CAR T-cell Therapies in Myeloma
Nurse Leadership Board
The Potential of CAR T-Cell Therapy and…
Resource
Making Myeloma Matter. Addressing the increased risk of multiple myeloma diagnosis in African Americans.…
Resource
Multiple myeloma (MM) patients often experience bone involvement, leading to painful vertebral compression fractures (VCFs) and deformities. Balloon kyphoplasty (BKP) and percutaneous vertebroplasty (PV) are minimally invasive procedures that can relieve pain and restore function in MM patients…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
2019 IMF Brian D. Novis Research Grants
Highlights from the 2018 ASH Meeting
iStopMM Is Leading the Way to a Cure – and…
Resource
Myeloma suppresses the immune system, reducing the number of normal antibodies and affecting all the cells that patrol for and attack abnormal cells.
Resource
This proteasome inhibitor is indicated for patients with myeloma who have received at least one prior therapy.
Resource
Protecting yourself and your medical information
Resource
Early diagnosis is key to achieving best outcomes for patients.
Resource
This immunostimulatory monoclonal antibody is used in combination with lenalidomide + dexamethasone.
Resource
Dear Reader
A message from IMF President Susie Durie
Scientific & Clinical
ASCENT Trial to Treat High-Risk Smoldering Multiple Myeloma Launching Across the US
Nurse Leadership Board…
Resource
This study examines the clinical predictors of long-term survival in multiple myeloma patients eligible for high-dose chemotherapy and autologous stem cell transplantation (HDM-ASCT). The analysis reveals that achieving complete response (CR) within the first year of diagnosis is associated with…
Resource
Myeloma Manager™ provides a tool to capture laboratory results and display and print tables and charts to show how those results change over time. Other features include automatic backup of your data each time you shut down the program, calendars, and graph features such as plotting multiple tests…
Resource
We’ve partnered with Smart Patients, an online community where patients and caregivers affected by complex illness learn from each other about treatments, challenges, and how it all fits into the context of their experience.
Resource
The Understanding series of cancer information booklets clearly and easily explain multiple myeloma treatments and care. Free for download.
Resource
A reference list of common acronyms and abbreviations that are used in myeloma.
Resource
Whole-body low-dose computed tomography (WBLDCT) is recommended as a first-line imaging modality for bone disease assessment in multiple myeloma patients. It offers higher sensitivity compared to conventional radiographs for detecting osteolytic lesions. Proper imaging parameters, such as thin-…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Highlights of the 2018 Annual Meeting of the American Society of Clinical Oncology
Highlights of the 2018 Summit of the…
Resource
This study examines the availability and access to multiple myeloma (MM) treatments in Latin American countries (LATAMC). It reveals disparities between public and private healthcare systems, with certain drugs being more accessible in one system over the other. The study emphasizes the need for…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Immunotherapy…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
2018 IMF Brian D. Novis Research Grants
Highlights of the 2017 Annual Meeting of the American Society of Hematology…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Darzalex in Frontline Therapy Clinical Trial
Kyprolis in Relapsed/Refractory Myeloma
Sixth Annual Master Class for…
Resource
Patients with multiple myeloma (MM) cope with short- and long-term side effects of the treatment as well as other conditions onset from the disease itself; and sometimes, comorbid health conditions. Symptoms may not be managed well due to many factors. This document includes patient-friendly…
Resource
Oncologic emergencies associated with multiple myeloma include myelosuppression (anemia, neutropenia, and thrombocytopenia), bone-related emergencies, and acute renal failure. This article reviews the pathophysiology of these multiple myeloma-associated oncology emergencies and provides a framework…
Resource
About 85% of patients with multiple myeloma develop bone disease. In these patients, lytic bone lesions can cause fractures, poor circulation, blood clots, pain, poor mobility, and decreased quality of life. This article presents consensus statements to guide nurses in the assessment and management…
Resource
Venous thromboembolism (VTE) and cardiovascular (CV) disease can occur in patients with multiple myeloma. Although VTE and CV disease are separate medical conditions, they can be serious and even life-threatening.
Resource
Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma
Resource
The psychological needs of patients and caregivers may be inadvertently overlooked, contributing to the patient’s distress and possibly compromising outcomes. Untreated, these psychological needs may impair the patient’s ability to make decisions and adhere to treatment.
Resource
Patients with multiple myeloma (MM) often deal with short- and long-term side effects of the treatment and disease sequelae. Reasons for inadequately managed symptoms are multifactorial (e.g., the patient may fear treatment interruption, the clinician does not assess or address the symptoms) and…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Report from the 2017 Summit of the International Myeloma Working Group
ASCO 2017 Highlights
IMF Honors Dr. Paul G.…
Resource
The document discusses a study comparing the use of whole-body computed tomography (WBCT) and conventional skeletal survey (CSS) in patients with multiple myeloma (MM). CSS has been the standard imaging technique for MM, but WBCT has recently been implemented into the diagnostic criteria. The…
Resource
Dear Reader
A message from IMF President Susie Novis
Scientific & Clinical
Black Swan Research Initiative® Progress Report
Promising Clinical Trials in 2017
Around the World in Three Days…
Resource
This study focuses on the natural history of relapsed multiple myeloma that is refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). The study included 543 patients diagnosed between 2006 and 2014 who had received at least three prior lines of therapy, were refractory to…
Resource
¹⁸F-FDG PET/CT is a valuable tool in the diagnosis, management, and monitoring of multiple myeloma, smouldering multiple myeloma, and solitary plasmacytoma. It can assess bone damage, detect extramedullary sites of clonal plasma cells, and provide prognostic information. The technique is…
Resource
Background: One constant and relatively unchanged aspect of treatment of multiple myeloma (MM) is the use of glucocorticosteroids, or steroids, which can cause a wide range of adverse side effects and harm patients’ quality of life.
Objectives: The objective of…